Chemical inhibitors of protein kinases

被引：295

作者：

Bridges, AJ ^{[1
]}

机构：

[1] Ann Arbor Labs, Pfizer Global Res & Dev, Ann Arbor, MI 48105 USA

来源：

CHEMICAL REVIEWS | 2001年 / 101卷 / 08期

关键词：

D O I：

10.1021/cr000250y

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

The role of Protein kinases as potential drug tragets was studied. The use of protein kinases for cellular signaling and cancer therapy was discussed. The chemical inhibitors of protein kinases like PKC and BCR-ABL along with epidermal growth factor receptor TK inhibitors and anilinopyrimidine inhibitors were also described.

引用

页码：2541 / 2571

页数：31

共 259 条

[1]

Adams J L, 1999, Curr Opin Drug Discov Devel, V2, P96

[2]

AFLALO E, 1994, CANCER RES, V54, P5038

[3] Relationship between flavonoid structure and inhibition of phosphatidylinositol 3-kinase: A comparison with tyrosine kinase and protein kinase C inhibition [J].

Agullo, G ;

GametPayrastre, L ;

Manenti, S ;

Viala, C ;

Remesy, C ;

Chap, H ;

Payrastre, B .

BIOCHEMICAL PHARMACOLOGY, 1997, 53 (11) :1649-1657

[4]

AKIYAMA T, 1987, J BIOL CHEM, V262, P5592

[5] Development of inhibitors for protein tyrosine kinases [J].

Al-Obeidi, FA ;

Lam, KS .

ONCOGENE, 2000, 19 (49) :5690-5701

[6] PD-098059 IS A SPECIFIC INHIBITOR OF THE ACTIVATION OF MITOGEN-ACTIVATED PROTEIN-KINASE KINASE IN-VITRO AND IN-VIVO [J].

ALESSI, DR ;

CUENDA, A ;

COHEN, P ;

DUDLEY, DT ;

SALTIEL, AR .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (46) :27489-27494

[7] Bcl-2-independent Bcr-Abl-mediated resistance to apoptosis:: protection is correlated with up regulation of Bcl-xL [J].

Amarante-Mendes, GP ;

McGahon, AJ ;

Nishioka, WK ;

Afar, DEH ;

Witte, ON ;

Green, DR .

ONCOGENE, 1998, 16 (11) :1383-1390

[8]

[Anonymous], 1998, GlaxoSmithKline WO, Patent No. [98/02438, 9802438]

[9]

ARNOLD LD, 1995, Patent No. 9523141

[10]

Barker A., 1993, Patent, Patent No. [EP0566226, 0566226]

← 1 2 3 4 5 6 7 8 9 10 →